Litcius/Paper detail

Deucravacitinib: First Approval

Sheridan M. Hoy

2022Drugs188 citationsDOIOpen Access PDF

Topics & Concepts

MedicinePsoriasisPsoriatic arthritisPlaque psoriasisDermatologyImmune systemDrugPharmacologyImmunologyPsoriasis: Treatment and PathogenesisCytokine Signaling Pathways and InteractionsIL-33, ST2, and ILC Pathways
Deucravacitinib: First Approval | Litcius